ADVERTISEMENT

Stay up to date every week with the european biotechnology newsletter.

✕
This field is hidden when viewing the form
EBcom NL
This field is hidden when viewing the form
Consent
This field is for validation purposes and should be left unchanged.

Stay up to date every week with the european biotechnology newsletter.

Log in here to read the desired article.

This field is hidden when viewing the form
EBcom NL
This field is hidden when viewing the form
Consent
This field is for validation purposes and should be left unchanged.
go to the article

go back to the homepage

  • BIOCOM CARD
  • Newsletter
  • Advertising
  • Job Market
  • Shop
European Biotechnology Magazine
biocom_logo
  • Latest news
  • Background
  • Opinion
  • The Mag
    • Issues
    • Special
    • Subscribe
  • Euro Biotech Guide
  • Market Place
    • Products
    • Sponsored Publications
    • Advertise
  • Associations
  • Service
    • Job Market
    • Newsletter
    • Contact Us
    • Editorial Team
  • Events
  • Search
  • Menu Menu

ADVERTISEMENT

LATEST NEWS

placeholder

Clinical trial disaster: report blames dru...

An expert panel’s final report on the fatal drug trial earlier this year in France states that the death of one of the participants was most likely caused by the drug’s toxicity and not by any violation … more ➔

placeholder

Argenx in cancer drug licensing deal

For up to US$685m (€606m), Dutch ArgenX has outlicensed its human antibody programme ARGX-115 to AbbVie. The pre-clinical immuno-oncology candidate targets a protein believed to contribute to immunosuppressive … more ➔

ADVERTISEMENT

Swiss biotech continues to do well

Despite political disturbances, 2015 was a good year for the biotech scene in Switzerland. Net sales increased by 5.1% to CHF5,133m and 400 additional people found jobs in the sector. As usual, the new … more ➔

placeholder

Recipharm in €68m Mitim takeover

Recipharm remains on track for growth. The Swedish CDMO is acquiring Italian injectable beta lactam expert Mitim Srl. The takeover is worth €68.4m. more ➔

Page 196 of 196«‹194195196

BACKGROUND

Vetter Prioritizes Continuity and Action in its Sus...

CARB-X

Antimicrobial resistance: Q&A with CARB-X abou...

Microsynth AG

Precision oligonucleotides for therapeutics

ADVERTISEMENT

MAGAZINE

1 / 4

This issue offers insights into Europe's fight for green solutions for a bioeconomy, antimicrobial resistance and how Europe is preparing for the next pandemic. more ➔

2 / 4

Since the first antibody drug was approved back in 1986, monoclonal antibodies have emerged as the dominant class in the global US$417bn market for biologics. At the end of 2023, sales stood at more … more ➔

3 / 4

The first half of 2024 is history, and experts are divided on whether the financing nadir has been reached or even passed. There are very different figures for different types of treatments under … more ➔

4 / 4

The Three R (Replacement, Reduction and Refinement) principles developed over 60 years ago provide a framework for more humane lab animal testing and, more importantly, less of it. A range of in-vitro … more ➔

❮❯

SPONSORED PUBLICATION

1 / 3
Sino Biological
Sino Biological

ADC Applications Beyond Oncology

Antibody-Drug Conjugates (ADCs) have been transformative in oncology, offering targeted cancer treatments that enhance efficacy while sparing healthy cells. However, the potential of ADCs extends … more ➔

2 / 3
GettyImages
The Altascientist

Discover the Dynamic Landscape of GLP-1 Drug Development

Explore the evolving world of GLP-1 receptor agonists in Issue 42 of The Altascientist, featuring insights on their expanding applications, early-phase development, and real-world case studies. more ➔

3 / 3
TriLink Biotechnologies
TriLink Biotechnologies

Fueling innovation with accessible mRNA products

Through a new partnership with VWR, TriLink Biotechnologies has made its catalogue of industry-leading nucleic acid technologies more available in Europe. By improving the ordering process and reducing … more ➔

newsletter_link
© BIOCOM Interrelations GmbH
  • LinkedIn
  • Instagram
  • Contact
  • Imprint
  • Privacy policy
Scroll to top